iSpecimen Inc. 2023 Q1 Form 10-Q Summary
Business context and reporting period
iSpecimen operates a single-segment online marketplace connecting medical researchers with hospitals, laboratories and other organizations supplying human biospecimens and related data. Revenue is generated primarily from procuring and delivering specimens to research customers. This unaudited Form 10-Q covers the three months ended March 31, 2023, compared with the three months ended March 31, 2022.
Financial performance and key metrics
| Metric | Q1 2023 | Q1 2022 | Change |
|---|---|---|---|
| Revenue | $2.95 million | $2.52 million | 17% increase |
| Cost of revenue | $1.15 million | $1.17 million | 2% decrease |
| Gross profit | $1.80 million | $1.35 million | Not separately reported; calculated |
| Gross margin | 61.1% | 53.7% | Improved; calculated |
| Total operating expenses | $5.49 million | $4.88 million | 13% increase |
| Loss from operations | $(2.54) million | $(2.36) million | 8% larger loss |
| Net loss | $(2.43) million | $(2.38) million | 2% larger loss |
| Net loss per share | $(0.27) | $(0.27) | Unchanged |
| Adjusted EBITDA | $(1.84) million | $(1.89) million | Improved by $0.05 million |
Revenue included $2.71 million from specimen contracts and $0.24 million from shipping and other activities. Specimen volume increased 75% to 8,629 specimens, while average selling price per specimen declined 30% to approximately $342.
Operating margin was approximately negative 86.2% in Q1 2023 versus negative 93.6% in Q1 2022. Net margin was approximately negative 82.4% versus negative 94.6%, calculated from reported results. Interest income increased to $114,263 from $12,654, primarily reflecting the company’s cash and Treasury bill investments.
Cash flow, liquidity and debt
- Cash used in operating activities was $2.83 million, compared with $1.38 million in Q1 2022.
- Cash used in investing activities was $8.79 million, including $7.24 million used to purchase U.S. Treasury bills and $1.54 million capitalized for internally developed software.
- Cash provided by financing activities was $67,736 from stock-option exercises.
- Cash and cash equivalents were $3.76 million at March 31, 2023, down from $15.31 million at December 31, 2022.
- Available-for-sale U.S. Treasury bills totaled $7.26 million, bringing cash and near-cash investments to approximately $11.0 million.
- Working capital was $12.11 million, compared with $15.39 million at December 31, 2022.
- The company reported no outstanding debt after repaying its $3.5 million term loan in November 2022. Current liabilities were $3.85 million, including $3.61 million of accounts payable and accrued expenses.
Management believes cash, cash equivalents, available-for-sale securities and anticipated operating cash flows are sufficient to fund operations for at least the next 12 months. Because of recurring losses, continued viability beyond May 2024 may depend on raising additional capital.
Material changes versus the prior comparable period
- Revenue increased 17%, driven by higher specimen volume and the recovery of supply activity following the disruption to Ukrainian and Russian suppliers in early 2022.
- Gross margin improved because average cost per specimen declined 43%, partially offsetting the lower average selling price.
- Technology expense increased 58%, sales and marketing expense increased 29%, and supply development expense increased 51%, reflecting increased staffing, software amortization, professional fees and network development costs.
- Operating cash consumption more than doubled, largely due to working-capital movements and continued investment in internally developed software.
- The company shifted approximately $7.2 million of cash into short-term U.S. Treasury bills to reduce concentration at a single bank following the March 2023 failure of Silicon Valley Bank.
- The allowance for doubtful accounts increased by $152,790 because several boutique life sciences customers filed for bankruptcy. The allowance totaled $383,789 at March 31, 2023.
- The company adopted the current expected credit loss standard on January 1, 2023, with no material effect on the financial statements.
Guidance, outlook, risks and unusual items
No formal numerical revenue or earnings guidance was provided. Under new Chief Executive Officer Tracy Curley, management is focused on increasing revenue in the second half of 2023, improving sales execution, increasing supplier-network utilization, reducing supplier concentration and accelerating technology development. The company capitalized approximately $1.54 million of software costs in Q1 and expects to continue investing at approximately that level for the remainder of 2023.
- Management expects technology investments to create additional revenue opportunities and operational efficiencies, with a stated expected rate of return of less than two years.
- Revenue and cash generation depend substantially on collecting unbilled and billed receivables and on customer demand for discretionary research procurement.
- Economic weakness, inflation, reduced research funding and customer bankruptcies could adversely affect demand and receivable collectability.
- The Russia-Ukraine war remains a supply-network risk. Although affected sites were mostly accessible at March 31, 2023, sanctions, renewed disruptions or supplier inaccessibility could affect fulfillment, margins and revenue.
- The company remains dependent on external capital over the longer term. Additional equity financing could dilute existing shareholders, while debt financing could increase interest costs and liquidity pressure.
- The Lexington, Massachusetts office lease expires February 28, 2024; the recorded operating lease liability was $147,375 at March 31, 2023.
- No material litigation, defaults upon senior securities or material changes to previously disclosed risk factors were reported.
- Potential dilution includes 216,058 unvested RSUs, 330,788 stock options and warrants exercisable for up to 1,415,000 shares as of March 31, 2023.
Important facts for investors to verify
- Whether the company’s revenue-growth initiatives produce sustained growth and improved operating leverage in the second half of 2023.
- The pace of operating cash burn and whether approximately $11.0 million of cash and Treasury bills remains sufficient for the company’s stated runway.
- Receivable collections, customer bankruptcies and changes in the $383,789 allowance for doubtful accounts.
- Actual returns from the continuing software investment program and the amount of costs capitalized versus expensed.
- Progress in reducing supplier concentration and the continuing operational impact of Russia-Ukraine disruptions.
- Whether additional capital will be required after the stated 12-month liquidity period and the potential dilution or financing cost associated with raising it.